Erbi Biosystems, a Woburn, MA-based microfluidic bioprocess instrumentation company based on technology developed at MIT, closed a $3.8M funding round.
The round was led by Jaguar Biotech.
The company intends to use the funds to expand manufacturing, sales and support of its existing 2mL, TruePerfusion™ Breez™ bioreactor, while also further develop its technology platform and product pipeline.
Led by Michael Chiu, PhD, CEO, Erbi Biosystems is focused on supporting therapeutic drug manufacturers with tools to accelerate the development of their processes and therapies. The company recently launched its first product, a microfluidic automated system, the Breez bioreactor, which delivers concentrated cell density performance for the expansion of intensified fed batch and continuous processing. The technology of microfluidic sensing and biological liquid handling was initially developed by the founders while at MIT.